Afatinib showed a median PFS of 11.97 months in a Taiwanese study on 5 patients suffering from stage IV lung adenocarcinoma and who had the EGFR L747P or L747S mutation, particularly in comparison to only 0.92 months with a first-generation EGFR-TKI (p = 0.012), further illustrating the drug’s ability to treat these uncommon mutations [25]. Here, EGFR is linked to lung adenocarcinoma.